Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0FEVOT
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
HN-02
|
|||||
| Synonyms |
HN02; HN 02
Click to Show/Hide
|
|||||
| Organization |
China Pharmaceutical University.; State Key Laboratory of Natural Medicines, Nanjing, China.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
|
|
||||||
| Antibody Name |
TG7
|
Antibody Info | ||||
| Antigen Name |
Signal transducer CD24 (CD24)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Site-specific conjugation-based engineered cysteine sites (CL-V211C)
|
|||||
2027 Update
ADC-specific functional property
Bystander Killing Effect
| Bystander Killing Effect | Description | Reference |
|---|---|---|
| yes |
The effect is one of the important factors in the biological activity of ADCs. After treating BEL7402 cells with 1000 nM of HN02 for 1 day, the survival rate of cells decreased from 96.816% to 79.456% when HCT116 cells were treated with the culture supernatant. As time went by, this decrease became more significant. After 2 or 3 days of treatment with 100 nM HN02, the average cell viability dropped to 66.542% and 62.600%, respectively.
Click to Show/Hide
|
[1]
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
55.29%
|
|||
| Method Description |
HN02-L (5 mg/kg): BEL7402 (2×106) cells were injected subcutaneously into the right side of BALB/C nude mice to establish a hepatocellular carcinoma xenograft model. After the mean tumor volume reached 50-100 mm3, the tumor-bearing mice were divided randomly into 5 groups (eight mice/group). TG7 (5 mg/kg), HN02-L (5 mg/kg), HN02-H (10 mg/kg), or saline were injected intravenously every 3 days, and the positive group was treated with the drug sorafenib (20 mg/kg) by gavage daily for 3 w. Body weights and tumor volumes were measured periodically, and tumor volume was calculated using the formula V=LW2 /2 (L: long diameter of the tumor, W: short diameter of the tumor in the vertical direction). All mice were executed on day 21 of treatment, and tumors were excised for subsequent analysis.
Click to Show/Hide
|
||||
| In Vivo Model | BEL7402 hepatocellular carcinoma model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
70.25%
|
|||
| Method Description |
HN02-H (10 mg/kg): BEL7402 (2×106) cells were injected subcutaneously into the right side of BALB/C nude mice to establish a hepatocellular carcinoma xenograft model. After the mean tumor volume reached 50-100 mm3, the tumor-bearing mice were divided randomly into 5 groups (eight mice/group). TG7 (5 mg/kg), HN02-L (5 mg/kg), HN02-H (10 mg/kg), or saline were injected intravenously every 3 days, and the positive group was treated with the drug sorafenib (20 mg/kg) by gavage daily for 3 w. Body weights and tumor volumes were measured periodically, and tumor volume was calculated using the formula V=LW2 /2 (L: long diameter of the tumor, W: short diameter of the tumor in the vertical direction). All mice were executed on day 21 of treatment, and tumors were excised for subsequent analysis.
Click to Show/Hide
|
||||
| In Vivo Model | BEL7402 hepatocellular carcinoma model | ||||
References